I'm not really involved in pharma, but there seems to be a decent argument for selling the drug with provisional approval after safety has been established and collecting outcomes data for those who use provisional drugs https://reason.com/2018/02/02/right-to-try-fda-drug-trials/
In pharma, I think the success criteria are much better understood, but it's just really hard to do what people want.
Not so say our regulatory system isn't a shitshow that needs reform, but I don't think there is the same benefit of releasing buggy versions.
Having said that, there are a lot of arguments for reforming how we do later stage clinical trials to provide access to potentially life saving drugs as well as reducing the costs of drug development https://reason.com/2018/02/02/right-to-try-fda-drug-trials/
It's kinda understandable given that some drugs can have serious negative long term effects on people, whereas a buggy CRUD app can't really do much harm in comparison.
While the costs of a "buggy" drug are usually larger than the cost of a buggy app, the benefits of a "good" drug are usually larger than the benefit of yet another app to share pictures, or a uber but for X.
Just see how much it costs to save the economy just from the corona measures. The opposite of that is the benefit of a 1 year increase of people's healthy life spans, much more in fact as only parts of the economy were shut down.